A phase I, multiple-dose study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma

Trial Profile

A phase I, multiple-dose study of SGN-40 (anti-huCD40 mAb) in patients with refractory or recurrent multiple myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Dacetuzumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 07 Oct 2011 Actual end date changed from Aug 2007 to Nov 2007 as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Genentech reported as a Sponsor by ClinicalTrials.gov.
    • 09 Oct 2008 Actual end date was Aug 2007, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top